We have previously shown that expression of the transcription factor HES-1 is required for the growthinhibitory effect of all-trans retinoic acid on MCF-7 cells. In this study, we have used T47D cells with tetracyclinregulated expression of wild-type or a dominant-negative form of HES-1. Expression of HES-1 in T47D cells inhibited G 1 /S-phase transition and activation of Cdk2 elicited by estrogen. Estrogen treatment of T47D cells caused increased expression of E2F-1, and this expression was inhibited by cotreatment with all-trans retinoic acid. We show that the effect is mediated through HES-1, which directly downregulates E2F-1 expression through a CACGAG-site within the E2F-1 promoter. Furthermore, proliferation caused by heregulin-b1 treatment of T47D cells was inhibited by all-trans retinoic acid and this effect was mediated by HES-1. Interestingly, heregulin-b1-mediated upregulation of E2F-1 expression was directly inhibited by HES-1 through the same CACGAG-site as seen with estrogen-stimulated induction. In addition, we found that two important downstream target genes of estrogen and heregulin-b1 that are regulated through E2F-1, cyclin E and NPAT, were both regulated in a similar fashion by all-trans retinoic acid, and these effects were antagonized by dominant-negative HES-1. These findings establish that HES-1 inhibits both estrogen-and heregulin-b1-stimulated growth of breast cancer cells, and further suggest that growth inhibition induced in these cells by all-trans retinoic acid occurs via HES-1-mediated downregulation of E2F-1 expression.
Introduction
Growth of human breast epithelial cells is dependent on estrogen as well as epidermal growth factor receptors. Estrogens are key-players in the development of breast cancer and have been reported to take part in the initial transformation as well as to play a major role in the progression to a malignant, neoplastic state (Tsutsui et al., 1987; Bergkvist et al., 1989; Nandi et al., 1995) . 17b-Estradiol (E 2 ) drives proliferation by affecting several cell-cycle factors. An important target gene induced by E 2 is the transcription factor E2F-1 . The members of the E2F-family of transcription factors (E2F-1-7) comprise key regulators of cellular proliferation, development, differentiation, and apoptosis (Muller et al., 2001) . E2F-1 is the bestcharacterized member of the E2F-family. Overexpression of E2F-1 can drive quiescent cells into S-phase and override many different types of cell cycle arrests Johnson et al., 1993) . In nonproliferating cells, the E2F factors are stably bound to members of the Rb pocket protein family (Dyson, 1998) . This association keeps the E2F in an inactive state and this complex can even function as an active repressor of transcription (Weintraub et al., 1992) . In the mid-G 1 phase, during cellular proliferation, E2F-pRb complexes dissociate as a result of hyperphosphorylation by Cdks and E2F-1 subsequently acts as a transcriptional activator and induces its own transcription through binding sites within the E2F-1 promoter (Nevins, 1998) . The high level of dissociated E2F-1 seen in mid-G 1 phase is essential for S-phase entry and proliferation.
There is a wealth of clinical data demonstrating the importance of ErbB receptors, in particular ErbB1 (EGF-receptor) and ErbB2 (HER2/Neu), in development and malignancy of human cancer (Holbro et al., 2003) . In MCF-7 cells, activation of ErbB3 by the growth factor ligand heregulin-b1 (HRG) induces ErbB2-ErbB3 heterodimerization and cellular proliferation (Jhabvala-Romero et al., 2003) .
In cell cultures, increased ErbB2 expression or HRG treatment leads to an estrogen-independent phenotype of breast cancer cells through crosstalk between the estrogen and ErbB receptors (Pietras et al., 1995; Tang et al., 1996) .
The natural vitamin A derivative all-trans retinoic acid (atRA) has antiproliferative effects on breast cancer cell lines (Zhu et al., 1997; Wang et al., 2000) including inhibition of the mitogenic actions of E 2 (Muller et al., 2002) . Previously, we have shown that expression of the transcription factor HES-1 is required for the growth inhibitory effect of atRA on the breast cancer cell line MCF-7 (Muller et al., 2002) .
HES-1 is a transcriptional repressor of the basic helix-loop-helix (bHLH) family with conserved structural features from Drosophila to humans. The factor is expressed in many tissues such as CNS, lung, kidney, intestine (Sasai et al., 1992; Fisher and Caudy, 1998) . The closely related factors HERP-1/HERP-2 can form a heterodimer with HES-1 which has a higher DNA binding affinity and stronger repressive function than respective homodimers (Iso et al., 2001) .
No direct HES-1 target genes with proliferative potential have been found. In this study, we have identified E2F-1 as a downstream target of HES-1 action, which may serve to explain the antiestrogenic effects of HES-1. In addition, we show that atRA opposes the proliferative response to HRG by increasing expression of HES-1 and directly inhibiting HRGstimulated upregulation of E2F-1.
Results

HES-1 expression arrests T47D cells in the G 1 phase of the cell cycle
We have previously shown that HES-1 expression is needed for the antiproliferative effect of atRA in MCF-7 cells (Muller et al., 2002) . To define the phase of the cell cycle in which HES-1 arrests the cells, flow cytometric analysis of DNA content was performed on T47D cells with tet-regulated HES-1 expression. Our studies demonstrated that, in synchronized T47D cells, removal of tet (induction of HES-1 expression (Strom et al., 2000) ), prevented progression of the cells through G 1 phase in response to E 2 treatment (Figure 1a ). Since these studies indicated growth arrest in the G 1 phase of the cell cycle, we investigated if Cdk2 activity was affected by HES-1 expression. As anticipated, we found that the activation of Cdk2 caused by E 2 treatment was inhibited by HES-1 expression (Figure 1b) , again indicating that HES-1 enforces a blockade of G 1 transit.
atRA downregulates E2F-1 through HES-1 expression It has previously been shown that atRA inhibits E 2 -induced expression of E2F-1 in MCF-7 cells (Zhu et al., 1997) as well as the proliferative effects of E 2 on these cells (Muller et al., 2002) . We decided to find out if exogenous HES-1 expression could prevent the upregulation of E2F-1 induced by E 2 (Foster et al., 2001) . For this purpose, we again used the T47D cells with tetregulated HES-1 expression; the results presented in Figure 2a and b indicated that overexpression of HES-1 blocked the increased E2F-1 expression observed following E 2 addition. Furthermore, treatment with atRA in the presence of E 2 had the same effect as overexpressing HES-1 (Figure 2b ). Previously, we have shown that E 2 downregulates HES-1 transcript and protein levels (Strom et al., 2000; Muller et al., 2002) ; therefore, HES-1 down-regulation may be required for E2F-1 upregulation by E 2 . The next question, was if functional HES-1 expression is required for atRA to downregulate E2F-1. To answer this question we used T47D cells with tet-regulated expression of dnHES-1 (Muller et al., 2002) . We found that E2F-1 expression was increased after 24 h of E 2 treatment in the presence of tet while addition of 1 mM atRA reduced expression of E2F-1 to its basal level (Figure 2c ). In the absence of tet, that is, with dnHES-1 induced, E 2 increased E2F-1 expression after 24 h and atRA was no longer able to inhibit E2F-1 expression (Figure 2c ). This suggests that functional HES-1 is essential for atRA's effect on E2F-1 expression.
Next, we wanted to find out if the observed regulation of E2F-1 could be reproduced at the promoter level. The E2F-1 promoter was upregulated following treatment with E 2 and furthermore, this upregulation was inhibited if atRA was added at the same time as E 2 ( Figure 2d ). If a HES-1 expression plasmid was cotransfected, the result was the same as with treatment with atRA, but if an expression vector for dnHES-1 was cotransfected, the inhibitory effect of atRA was eliminated (Figure 2d) . Analysis of the proximal E2F-1 promoter revealed the presence of a consensus element CACGAG known to bind HES-1 (Ohsako et al., 1994) . We mutated this element and found that the promoter was no longer repressed by HES-1 expression ( Figure 3a) . Furthermore, we found that purified GST-HES-1 protein was able to bind to the wild-type element, while the mutated element did not bind ( Figure 3b ). In addition, using nuclear extracts from T47D cells, we found that HES-1 bound as a homodimer to the HES-1 binding site in the HES-1 promoter but binding to the HES-1 binding site in the E2F-1 promoter was only present as a faster migrating band which could be competed with a HES-1 binding oligo Reduction of E2F-1 expression by atRA is dependent on HES-1 J Hartman et al indicating that this band is a heterodimer between HES-1 and the related factor HERP-1/2 described by Iso et al. (2001) . Extracts from cells exposed to atRA showed an increased binding of the HERP-1/2-HES-1 heterodimer ( Figure 3c ).
It is well established that expression of cyclin E increases in mid-to-late G 1 phase, that forced expression of this factor can cause cell cycle progression (Lukas et al., 1997) and that cyclin E is a target of E2F-1 . We analysed whether atRA and HES-1 could affect expression of cyclin E in T47D HES-1 cells treated with E 2 . Since cyclin E is known to be regulated at both the promoter and protein levels, we started by looking at the latter. Treatment with E 2 upregulated cyclin E at the protein level; however, cotreatment with atRA prevented this induction ( Figure 4a ). We then used the T47D dnHES-1 cell line and found that expression of dnHES-1 prevented atRA from inhibiting cyclin E expression ( Figure 4b ). By transfection of the À207 cyclin E promoter-luc reporter construct into T47D cells, we could show that E 2 stimulated promoter activity, while treatment with atRA in combination with E 2 inhibited activation of the promoter. In addition, cotransfection of a HES-1 expression plasmid made the promoter nonresponsive to E 2 (Figure 4c ), an effect reversed by overexpression of E2F-1.
NPAT is a newly discovered target gene of E2F-1 (Gao et al., 2003) and we wanted to know if NPAT is also repressed by induced HES-1 expression in T47D cells. By using the T47D dnHES-1 cell line, we found that treatment with atRA prevented E 2 induction of NPAT mRNA, while expression of dnHES-1 reversed the effects of atRA (Figure 4b ). Transient transfections with the NPAT promoter showed increased activity by treatment with E 2 , an effect that was abolished by cotreatment with atRA or cotransfection with HES-1. In addition, we could show that repression of the NPAT promoter activity by HES-1 was counteracted by forced expression of E2F-1 (Figure 4c ). This may indicate that, under our conditions, regulation of NPAT expression by E 2 and repression by HES-1 is primarily mediated through E2F-1.
Heregulin b1 induced proliferation of T47D cells is inhibited by atRA, an effect dependent on HES-1 expression It has previously been shown that treatment of T47D cells with HRG increases proliferation (Marte et al., 1995) . Since atRA inhibited proliferative effects of another mitogen (E 2 ), we asked whether HRG-induced proliferation could be counteracted by atRA treatment. Synchronized T47D HES-1 cells, in the presence of 1 mg/ml of tet, treated with HRG, showed a robust increase in proliferation rate, while HRG treatment in the absence of tet, that is, with exogenous HES-1 expression, did not lead to increased proliferation (Figure 5a ). Similarly, atRA inhibited the increased cellular proliferation caused by HRG. Next, we wanted to know if this inhibitory effect of atRA depended on Figure 2 Exogenous HES-1 inhibits E 2 induction of E2F-1 at mRNA, promoter, and protein levels. (a) Synchronized T47D HES-1 cells were treated with 10 nM E 2 and 7tet. Cells were lysed with Trizol and cDNA was prepared for real-time PCR with E2F-1-specific primers. (b) Cells were treated with 10 nM E 2 71 mM atRA, respectively, and with 1 mg/ml tet as indicated. Cells were harvested to make NP40 protein extracts at 0 and 24 h as described in 'Materials and methods'. A measure of 50 mg of protein extract per well was used for immunoblotting. (c) Synchronized T47D dnHES-1 cells were treated with 10 nM E 2 , 1 mM atRA and 7tet for 0 and 24 h. cDNA was prepared and real-time PCR was performed with E2F-1-specific primers. (d) Transfections of the -238 E2F-1 LUC plasmid into untreated, synchronized T47D cells followed by treatment with 10 nM E 2 , 1mM atRA and cotransfection with pcDNA3 HES-1 or pcDNA3 dnHES-1 as indicated. 18 s rRNA was used as a reference gene in real-time PCR-assays. Results in graphs are mean7s.d. of at least triplicate wells. Statistical analysis was performed with unpaired t-test. All experiments were repeated twice with similar results
Reduction of
HES-1 expression, and for this purpose we used the T47D dnHES-1 cell line. Treatment with HRG in the presence of tet (no dnHES-1) led to an increased cellular proliferation; simultaneous treatment with 1 mM atRA aborted this stimulation of proliferation. Removal of tet, that is, expression of dnHES-1, did not affect HRGinduced cellular proliferation, but the proliferation could no longer be inhibited by treatment with atRA ( Figure 5b ). To determine if HES-1-mediated downregulation of E2F-1 could be involved in the inhibitory effect of atRA on cellular proliferation stimulated by HRG, we treated T47D HES-1 cells and found that HRG increased E2F-1 expression threefold by 24 h while atRA inhibited this increase in mRNA expression. Removal of tet, that is, expression of exogenous HES-1, completely blocked the increase in E2F-1 mRNA level and reduced it to the same extent as treatment with atRA ( Figure 5c ). We then used the E2F-1 promoter to investigate if HRG directly affected the promoter activity by regulating HES-1. As can be seen in Figure 5d , the wt E2F-1 promoter activity was increased by treatment with HRG and repressed by cotransfection with HES-1. While the activity of the mutated E2F-1 promoter was increased by HRG it could no longer be repressed by HES-1 suggesting an important role of the CACGAG consensus sequence in the E2F-1 promoter. Taken together, these results suggest that HRG-induced proliferation is abrogated by HES-1 and that repression of the growth response by atRA may be related to the abolition of the HRG-induced E2F-1 transcription by HES-1-mediated repression.
Discussion
HES-1 has been shown to play an important role during development and differentiation. Here, we show that this factor is also involved in regulating cell growth of human breast carcinoma cells. atRA is well known for its antiproliferative effect in breast carcinoma cell lines. Earlier studies in MCF-7 cells have indicated a regulation of E2F-1 by atRA (Zhu et al., 1997) ; we show here that the regulation of E2F-1 by atRA is mediated through HES-1. Treatment of MCF-7 cells with atRA upregulates HES-1 at both the mRNA and protein levels (Muller et al., 2002) . Furthermore, we find that HES-1 binds to the E2F-1 promoter and represses its transcription (Figure 3a, b) . In addition, our results indicate that endogenous HES-1 binds to the E2F-1 promoter as a heterodimer with the related protein (Figure 3c ). HES-1/HERP-1/2-heterodimers have been reported to function as even stronger repressors than HES-1 alone (Iso et al., 2001) . Binding of HES-1 to a promoter has only been demonstrated in few cases, besides its binding to its own promoter (Takebayashi et al., 1994) . The fact that HES-1 directly regulates E2F-1 will affect expression of many genes downstream of this central transcription factor. Thus, cyclin E expression was found to be repressed by atRA; it is likely that this is mediated through E2F-1. Cyclin E/ Cdk2 is one of the major regulators of G 1 /S phase transition and functions, in part, by phosphorylating pRB, leading to subsequent dissociation of E2F, which then activates transcription of target genes (Hinds et al., 1992) . Free E2F-1 binds to its own promoter and induces transcription, resulting in high levels of E2F-1 in the G 1 phase of proliferating cells (Nevins, 1998) . Therefore, inhibition of E2F-1 transcription caused by treatment with atRA should lead to a profound decrease in the level of E2F-1 as observed in Figure 2b . A recent study has shown that inhibition of E2F-1 transcription by siRNA in breast cancer cells blocks Rb-phosphorylation and interference of this feed-forward loop would be an efficient barrier to neoplastic cell cycling (Shen et al., 2004) .
So far, we have studied two different E 2 -responsive breast cancer cell lines and our results indicate that, in both cases, HES-1 has to be downregulated for E 2 to stimulate cellular proliferation (Strom et al., 2000; Muller et al., 2002) . In our experiments, E2F-1 was upregulated in response to both E 2 and HRG, but inhibited by atRA through HES-1. We believe that this mechanism is an important component of the antiproliferative effect of atRA mediated through HES-1. Since E2F-1 is a corner stone in many cell-fate decisions (Muller et al., 2001) , it is interesting to speculate that HES-1 might be involved in not only regulation of proliferation but also in differentiation, apoptosis and development of breast epithelial cells.
A schematic representation of different HES-1 associated signaling pathways acting on E2F-1, as defined in the present paper, is given in Figure 6 .
The fact that HES-1 downregulates a central cell cycle gene like E2F-1 makes HES-1 a potential tumor suppressor gene. However, no mutations of the HES-1 gene have been found to be associated with cancer. Furthermore, HES-1 is expressed in many cancer cell lines indicating the presence of a mechanism for inactivation of HES-1. A recent paper reporting increased expression of HES-6 in primary cancer and in metastases might explain how HES-1 activity is neutralized (Swearingen et al., 2003) , since HES-6 antagonizes HES-1 by forming a nonfunctional HES-6/ Figure 4 Exogenous expression of HES-1 inhibits induction of cyclin E and NPAT by E 2 ; HES-1 expression is needed for inhibitory effect by atRA. (a) T47D dnHES-1 cells were synchronized and treated with 10 nM E 2 , 1 mM atRA and 1 mg/ml of tet as indicated for 24 h. cDNA was prepared and real-time PCR was performed with cyclin E and NPAT specific primers. (b) T47D HES-1 cells were synchronized and treated with 1 mM atRA, 10 nM E 2 and 1 mg/ml of tet as indicated. Protein extracts were prepared, as described in 'Materials and methods', at 0 and 24 h. A measure of 50 mg of protein extracts were loaded per well. (c) Transfections of the À207 cyclin E LUC or the -134 NPAT LUC plasmid, respectively, into normal, synchronized T47D cells followed by treatment with 10 nM E 2 , 1 mM atRA and cotransfection with pcDNA3 HES-1 and CMV E2F-1, as indicated. 18 s rRNA was used as a reference gene in real-time PCR-assays. Results in graphs are mean 7s.d. of at least triplicate wells. Statistical analysis was performed with unpaired t-test. All experiments were repeated twice with similar results
Reduction of E2F-1 expression by atRA is dependent on HES-1 J Hartman et al HES-1 heterodimer lacking transcriptional repressor activity (Bae et al., 2000) . Interestingly, amplification of the genomic region where HES-6 is located has been found in several cancers (Swearingen et al., 2003) . Many hormone-independent breast tumors overexpress ErbB-receptors and/or HER-2, and these proteins could be involved in development of the hormoneindependent phenotype (Pietras et al., 1995; Tang et al., 1996) . Therefore, it is interesting that HES-1 also inhibits HRG-mediated proliferation and induction of E2F-1. This indicates that, in our cell system, HES-1 has an antiproliferative effect in several stages of the tumor development. In addition, HES-1 might be a general inhibitor of mitogenic action in other cell types as well.
Materials and methods
Cell cultures, plasmids and transfections T47D cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 5% fetal bovine serum (FBS), 1% penicillin-streptomycin (Invitrogen) and 0. 1% kanamycin (Sigma). For experimental conditions, stripped medium was used, that is, phenol red-free medium (Invitrogen) supplemented with dextran/charcoal-treated FBS. Synchronization, transient transfections and nuclear extracts were done as described earlier (Muller et al., 2002; Strom et al., 2004) . E 2 Figure 5 Expression of HES-1 inhibits heregulin-b1 stimulated proliferation and induction of E2F-1; HES-1 expression is required for inhibition by atRA. (a) T47D cells with tet-regulated HES-1 were plated at 5000 cells/cm 2 and synchronized using ICI 182,780. The cells were washed with PBS and stripped medium containing 50 ng/ml HRG and 1 mg/ml of tet added as indicated. Proliferation was measured at day 5. (b) In the case of dnHES-1 T47D cells, 50 ng/ml HRG, 1 mM atRA and 1 mg/ml of tet were added. The cells were cultured for 6 days whereupon proliferation assay was performed as described in 'Materials and methods'. Values are means7s.d. (n ¼ 6). Statistical significance was determined by unpaired t-test. (c) T47D cells were cultured on six-well plates at 50% confluence and synchronized. The cells were then treated with HRG and atRA as stated and E2F-1 mRNA levels were determined as in Figure 2 . 18 s rRNA was used as a reference gene in real-time PCR-assays. (d) Transient transfections of the wt E2F-1 promoter or E2F-1 promoter construct with mutated CACGAG HES-1 binding element into T47D cells. Results in graphs are mean 7s.e. of at least triplicate wells. Statistical analysis was performed with unpaired t-test. All experiments were repeated twice with similar results
Figure 6 Overview of factors affecting E2F-1 expression in T47D cells
Reduction of E2F-1 expression by atRA is dependent on HES-1 J Hartman et al (Sigma) and ICI 182,780 (Tocris) were dissolved in ethanol and atRA and 4OH-tamoxifen (both from Sigma) were dissolved in DMSO. E 2 and ICI 182,780 were used at 10 nM concentrations for incubations. atRA was incubated at 1 mM and HRGb1 EGF domain (R&D Systems) at 50 ng/ml. Reporter plasmids (1.0 mg/well) were transiently cotransfected together with expression plasmids (0.5 mg). All data were normalized to b-galactosidase enzyme activity obtained after transfection with a b-galactosidase-lacZ plasmid (100 ng/well). The À207 cyclin E LUC plasmid was kindly provided by JR Nevins ; the À238 E2F-1 LUC plasmid and the CMV-E2F-1 expression plasmid were generously provided by M Bondesson (Nygard et al., 2003) . The NPAT-promoter -134 to þ 21 was amplified by PCR from human genomic DNA with primers GCG AAC GGA GGC GGG TTT CAT TT and TAA AGC AAA CAC AGC GAC AGC T.
For stable transfections, Flag-tagged HES-1 (HES-1) or Flag-tagged dominant negative HES-1 (dnHES-1) (Muller et al., 2002) were used as described (Strom et al., 2004) .
Western immunoblotting analysis and kinase assays
Cells were plated and grown in 150 mm plates until 50% confluence was reached before replacement with stripped medium including E 2 , HRG and/or atRA. Harvesting and extraction were done at different times (0-24 h) according to standard protocol. SDS-PAGE was performed as described (Muller et al., 2002) . The following primary antibodies have been used: cyclin E (sc-247, Santa Cruz), E2F-1 (sc-251, Santa Cruz) and b-actin (Sigma). Immune complex histone kinase assays were performed as described (Foster and Wimalasena, 1996; Foster et al., 2001) , using rabbit polyclonal antibodies to Cdk2 (M2) (Santa Cruz).
Flow cytometric analysis
For flow cytometric analysis, growth arrested or stimulated T47D cells were harvested in saline-EDTA, fixed in cold 70% ethanol and stored at -201C. Fixed cells were subsequently washed, treated with 100 mg/ml RNAse A, and stained with 50 mg/ml propidium iodide. Analysis of DNA content was performed in a Becton-Dickinson FACScan with a minimum of 15 000 events collected for analysis using Becton-Dickinson Cell Quest software. The proliferative fraction in the culture was determined as cells in the S and G 2 /M phases of the cell cycle based on DNA content.
cDNA synthesis and real-time PCR RNA extraction and cDNA synthesis were performed as described (Muller et al., 2002) . cDNA was amplified in a realtime PCR using TaqMan Universal Master Mix or SYBRgreen Master Mix (PE Applied Biosystems). The following primers and probes were used: E2F-1 (Taqman) forward primer (300 nM); 5 0 -CTC CTG AGA CCC AGC TCC AA-3 0 , reverse primer; 5 0 -ATC CCA CCT ACG GTC TCC TCA-3 0 , probe (300 nM); 5 0 -FAM (6-carboxyfluorescein)-CT CTT CGG AGA ACT TTC AGA TCT CCC TTA AGA GC-TAMRA (6-carboxytetramethylrhodamine)-3 0 . Cyclin E (SYBR-green) forward primer; 5 0 -GGA AGA GGA AGG CAA ACG TGA-3 0 , reverse primer; 5 0 -TCG ATT TTG GCC  ATT TCT TCA T-3 0 . NPAT (SYBR-green) forward primer; 5 0 -GGA AGA AAT TGG ACC ATA CAC TTT C-3 0 , reverse primer; 5 0 -CTC TGA CTG CCA GCA AAC CTT-3 0 . The realtime PCR reactions were performed in an ABI PRISM Model 7700 sequence detector (Applied Biosystems) under the following conditions: 501C for 2 min, 951C for 10 min, followed by 40 cycles at 951C for 15 s and 601C for 1 min. The optimum concentration of primers and probe was determined in preliminary experiments. The 18s-rRNA (PreDeveloped TaqMan Assay Reagents, Applied Biosystems) was used as a reference gene.
Proliferation assay
Cells were plated at a density of 5000 cells/cm 2 . After 24 h, the medium was replaced with charcoal-stripped medium and ICI 182,780. After an additional 48 h, the cells were washed with PBS and stripped medium was added in combination with different treatments. Tet was maintained in the medium or removed as indicated in the figure legends. After 6 days of growth, proliferation assay was performed as described previously (Muller et al., 2002) .
Electrophoretic mobility shift assay
A measure of 20 pmol of synthetic double-stranded oligonucleotide were end-labeled using [g-32 P]ATP and T4 polynucleotide kinase (Amersham Biosciences). The sequences of used oligonucleotides were as follows: wt E2F1 GAT CCG GCG GCT CGT GGC TCT A, mut E2F1 CGG CGG CTC GTT GCT CTT TCG CGG, HES-1 AGC GGT GCC GCG TGT CTT GGA GCT with the HES-1 binding site underlined. Purified GST-HES-1 protein was incubated for 15 min at room temperature with 0.5 mg of poly(dI-dC)(Amersham Biosciences), 10 mM DTT and 100 mM NaCl. After addition of end-labeled oligonucleotide, the mixture was incubated for additional 15 min at room temperature. Nuclear extracts was prepared according to Schreiber et al. (1989) . For the competition assays an excess of nonlabeled oligonucleotide was added and incubated for 15 min at room temperature prior to addition of the labeled one. The mixtures were loaded onto a 5% nondenaturing polyacrylamide gel and electrophoresed at 240 V in Tris/borate/EDTA buffer. The gel was dried prior to visualization by autoradiography.
Abbreviations E 2 , 17b-estradiol; atRA, all-trans retinoic acid; HRG, heregulin-b1 EGF-domain; Tet, tetracycline; dnHES-1, dominantnegative HES-1.
